Biocon Limited
BIOCON.NS
₹416.50
▼ 2.55%
Biocon shares slipped 2.55% to ₹416.50, even after the company notched a regulatory win with Health Canada's approval for its ustekinumab autoinjector, Yesintek. The drag on the counter appears linked to news that Viatris/Mylan plans to offload up to 92 million shares worth close to ₹3,481 crore, a stake sale of that size typically weighing on sentiment regardless of underlying fundamentals. On the operational side, partner Duopharma secured insulin supply contracts worth over MYR 225 million from Malaysia's health ministry, and the board declared a final dividend of ₹0.50 per share for FY26. Despite today's fall, the stock is still trading close to its 52-week high of ₹447.15, well above its low of ₹331, and carries a "Buy" consensus with a 12-month target near ₹423.70.
CAGR Performance
| 1 Year | 2 Years | 5 Years | 10 Years |
|---|---|---|---|
| 15.59% | 11.14% | 2.31% | 11.42% |
No comments:
Post a Comment